The note reveals that Goldman has initiated coverage with a buy rating and $48.90 price target on ResMed's shares. Based on ...

Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.

Goldman Sachs initiated coverage of ResMed (RMD) with a Buy rating and A$48.90 price target The firm says its Buy thesis is based on “robust” ...

by Ishai Menache, Jeevan Pathuri, David Simchi-Levi and Tom Linton Companies face a variety of complex challenges in designing and optimizing their supply chains. Increasing their resilience ...

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

Fintel reports that on January 10, 2025, Piper Sandler initiated coverage of ResMed (NYSE:RMD) with a Neutral recommendation.

Adam Maeder, an analyst from Piper Sandler, has initiated a new Hold rating on Resmed (RMD).Stay Ahead of the Market:Discover outperforming ...

The global continuous positive airway pressure (CPAP) market is projected to reach a value of USD 900 million by 2033, ...

KYIV, Ukraine—When the director of Russia’s largest film studio met President Vladimir Putin in the Kremlin last month, he made sure to highlight how he had supported the war effort—by ...

ResMed Inc. (RMD), based in San Diego, California, is a leading provider of cloud-connected devices and digital health solutions, impacting millions of patients worldwide. With a market ...

Keeping CPAP Equipment Clean CPAP manufacturers ... exposure to it may compromise the body's ability to fight respiratory infections. As of February 1, 2020, ResMed has indicated that ozone damage ...